KPV official-source update · version 1
This page preserves this version’s findings and source pins. Open the current profile →
Official-source update
Reviewed 2026-09-19 · Preserved version 1
The nominated evidence was not a human treatment program
FDA’s July 2026 briefing found that the submitted references concerned animal work or skin permeation using human cadaver skin. These are distinct from administering KPV to living participants. FDA PDF pp. 20 ↗
More findings and the sources behind them
Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision.
The absence claim has a defined source and scope
FDA reported finding no clinical studies supporting KPV for wound healing or inflammatory conditions in its evaluation. This is an attributed search finding, not proof that no relevant record could exist anywhere. FDA PDF pp. 20, 21 ↗
Safety remains uncharacterized in the reviewed evidence
The briefing found no human pharmacokinetic or clinical safety studies. Its adverse-event search retrieved no reports, but FDA explicitly explains why passive reporting cannot establish safety. FDA PDF pp. 26 ↗
Quality questions matter even for a short peptide
FDA identified missing characterization and formulation data and insufficient information about aggregation and immunogenicity. A three-amino-acid sequence alone did not resolve those product-level questions. FDA PDF pp. 27, 28 ↗
What remains to be checked
- Check subsequent advisory records and any final FDA action separately from the staff briefing.
- Retrieve and appraise the original human reports and proposed formulation or route; agency search findings are dated and do not establish a complete worldwide literature review.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
FDA kpv briefing for the July 2026 advisory meeting ↗
Source dated 2026-07-23; retrieved 2026-09-19.
- The nominated evidence was not a human treatment program · PDF pp. 20 of 38
- The absence claim has a defined source and scope · PDF pp. 20, 21 of 38
- Safety remains uncharacterized in the reviewed evidence · PDF pp. 26 of 38
- Quality questions matter even for a short peptide · PDF pp. 27, 28 of 38
SHA-256:
0253b86534700fc72a48cccab7b10c19201102da831ef7a8a28e8dab09fea254